Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) filed a European patent application on May 5, 2026 for novel, non‑hallucinogenic neuroplastogen-derived compounds targeting PTSD and other mental health disorders. The filing is part of Clearmind’s exclusive worldwide license from Yissum, granting global development, manufacturing, and commercialization rights.
The company said the filing strengthens its intellectual property position in Europe. The announcement cites a 2025 PTSD market valuation of USD 18.5 billion and a projected USD 30.2 billion by 2035. The release also references an April 18, 2026 executive order directing faster federal review of psychedelic-based therapies.
Positive
- Exclusive global license from Yissum for the compounds
- European patent application filed, strengthening IP in a major market
- Targeting PTSD within a market valued at $18.5B in 2025
Negative
- Compounds remain investigational and are not approved for clinical use
- Company is responsible for advancing development, implying development cost and regulatory risk
- Patent application is filed but not yet granted in Europe
News Market Reaction – CMND
In the May 5 session, CMND declined 9.56%, reflecting a notable negative market reaction. Argus tracked a trough of -19.4% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | BTD evaluation update | Positive | -10.1% | Evaluating CMND-100 for potential FDA Breakthrough Therapy Designation in AUD. |
| Apr 20 | Policy support news | Positive | -28.1% | Company response to U.S. Executive Order prioritizing psychedelic breakthrough therapies. |
| Apr 20 | Clinical safety results | Positive | +58.4% | CMND-100 met primary safety and tolerability endpoint in Phase I/IIa AUD trial. |
| Apr 15 | DSMB recommendation | Positive | -28.6% | Independent DSMB gave positive recommendation to continue CMND-100 AUD trial. |
| Apr 14 | Endpoint achievement | Positive | -36.4% | CMND-100 met primary endpoint in FDA-approved Phase I/IIa AUD trial with good safety. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows frequent negative price reactions to generally positive clinical and policy news, with one sharp upside move on a key clinical milestone.
Over the last few weeks, Clearmind reported multiple positive updates on its non-hallucinogenic MEAI candidate CMND-100, including meeting primary safety and tolerability endpoints in an FDA‑approved Phase I/IIa Alcohol Use Disorder trial and favorable DSMB reviews on Apr 14–15, 2026. It also highlighted supportive U.S. policy moves and evaluated potential FDA Breakthrough Therapy Designation. Despite mostly constructive news, shares often fell after announcements, except for a strong +58.42% move on a key clinical endpoint update.
Key Terms
post-traumatic stress disorder (ptsd) medical
psychedelic-based therapies medical
executive order regulatory
cagr financial
neuroplastogen-derived therapeutics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, Canada, May 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a European patent application for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (PTSD) and other mental health disorders.
The European patent application forms part of the Company’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). Under the terms of the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize novel compounds developed at Yissum. The Company is responsible for advancing the development program in accordance with regulatory requirements.
According to recent market reports, the global post-traumatic stress disorder (PTSD) treatment market is valued at approximately USD 18.5 billion in 2025 and is projected to reach USD 30.2 billion by 2035, growing at a CAGR of
This filing further strengthens Clearmind’s robust intellectual property position in Europe, one of the world’s largest pharmaceutical markets. The move is particularly timely and significant in light of President Donald J. Trump’s Executive Order signed on April 18, 2026, which directs federal agencies to accelerate research, development, and regulatory review of psychedelic-based therapies for serious mental health conditions, including PTSD and substance use disorders. The order reflects a strong positive momentum and supportive policy environment for the advancement of innovative treatments in this field, especially for veterans and patients with unmet medical needs.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of the global post-traumatic stress disorder (PTSD) treatment market, advancing the development program with Yissum in accordance with regulatory requirements and strong positive momentum and supportive policy environment for the advancement of innovative treatments in PTSD treatment market, especially for veterans and patients with unmet medical needs. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
